ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
13 nov. 2017 07h00 HE
|
ProQR Therapeutics N.V.
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital...
Immuron Successfully Completes NASH Phase II Clinical Study Milestone
09 nov. 2017 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
Devonian annonce l’initiation de l’étude clinique de Phase IIa du Thykamine(MC) chez les patients atteints de Dermatite Atopique légère à modérée
09 nov. 2017 08h45 HE
|
Groupe Santé Devonian Inc.
NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS QUÉBEC, 09 nov. 2017 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSX...
Devonian Announces Initiation of Phase IIa Clinical Trial of Thykamine™ in Adult patients with Mild-to-Moderate Atopic Dermatitis
09 nov. 2017 08h45 HE
|
Devonian Health Group Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES QUEBEC CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ("Devonian" or the "Corporation")...
Helmsley Charitable Trust Awards $52 Million to Support the Global Platform for the Prevention of Autoimmune Diabetes
06 nov. 2017 09h00 HE
|
The Leona M. and Harry B. Helmsley Charitable Trust
New York, NY, Nov. 06, 2017 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust today announced five new grants that will support the European, multinational Global Platform for...
JDRF-Funded Study on Continuous Glucose Monitoring (CGM) in Pregnant Women with Type 1 Diabetes Shows Improved Outcomes for Their Newborns
31 oct. 2017 14h36 HE
|
Juvenile Diabetes Research Foundation Canada
TORONTO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Babies born to women with type 1 diabetes (T1D) may soon be at a reduced risk of complications after a JDRF-funded study revealed that observing blood...
VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million
30 oct. 2017 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)
26 oct. 2017 10h23 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Vaccinex Inc. today announced the dosing of the first patient in a Phase Ib/II study of VX15/2503, an investigational humanized anti-semaphorin 4D...
VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million
26 oct. 2017 09h29 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
25 oct. 2017 16h01 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...